1. Home
  2. IVVD vs ANTA Comparison

IVVD vs ANTA Comparison

Compare IVVD & ANTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • ANTA
  • Stock Information
  • Founded
  • IVVD 2020
  • ANTA 2022
  • Country
  • IVVD United States
  • ANTA Singapore
  • Employees
  • IVVD N/A
  • ANTA N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • ANTA Investment Bankers/Brokers/Service
  • Sector
  • IVVD Health Care
  • ANTA Finance
  • Exchange
  • IVVD Nasdaq
  • ANTA Nasdaq
  • Market Cap
  • IVVD 351.6M
  • ANTA 291.0M
  • IPO Year
  • IVVD 2021
  • ANTA 2025
  • Fundamental
  • Price
  • IVVD $1.75
  • ANTA $11.58
  • Analyst Decision
  • IVVD Strong Buy
  • ANTA Strong Buy
  • Analyst Count
  • IVVD 5
  • ANTA 2
  • Target Price
  • IVVD $5.11
  • ANTA $19.25
  • AVG Volume (30 Days)
  • IVVD 5.6M
  • ANTA 26.6K
  • Earning Date
  • IVVD 11-13-2025
  • ANTA 08-12-2025
  • Dividend Yield
  • IVVD N/A
  • ANTA N/A
  • EPS Growth
  • IVVD N/A
  • ANTA N/A
  • EPS
  • IVVD N/A
  • ANTA 0.24
  • Revenue
  • IVVD $46,210,000.00
  • ANTA $56,997,910.00
  • Revenue This Year
  • IVVD $112.35
  • ANTA $65.94
  • Revenue Next Year
  • IVVD $272.14
  • ANTA $59.39
  • P/E Ratio
  • IVVD N/A
  • ANTA $46.96
  • Revenue Growth
  • IVVD 1941.08
  • ANTA 405.62
  • 52 Week Low
  • IVVD $0.35
  • ANTA $10.19
  • 52 Week High
  • IVVD $2.74
  • ANTA $27.72
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 64.77
  • ANTA N/A
  • Support Level
  • IVVD $1.56
  • ANTA N/A
  • Resistance Level
  • IVVD $2.01
  • ANTA N/A
  • Average True Range (ATR)
  • IVVD 0.19
  • ANTA 0.00
  • MACD
  • IVVD 0.03
  • ANTA 0.00
  • Stochastic Oscillator
  • IVVD 72.92
  • ANTA 0.00

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About ANTA Antalpha Platform Holding Company Ordinary Shares

Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.

Share on Social Networks: